It was hoped that such PPAR-pan agonists would increase hepatic fatty acid oxidation by stimulating PPAR-α and PPAR- δ, and further improve insulin sensitivity by stimulating all three PPARs, and thus favourably influence conditions associated with the metabolic syndrome and type two diabetes mellitus (T2DM), whilst the negative effects, such as increased adiposity caused by PPAR-γ leading to weight gain would be negated by increased fat oxidation promoted by PPAR-α and PPAR-δ. Here, PPARA is linked to metabolic syndrome.